Trailhead Biosystems Inc. products

We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients. CAR T-cell therapy involves the treatment of cancer by modifying a patient’s T-cells in the lab so they will attack cancer cells. If clinical development of the CART T-cell produces the wrong T-cell subtype, patient outcome will suffer. Our T-Cell Subtype cell therapy program aims to improve the efficacy of CAR T-cell therapies.

We are developing human endothelial cells from human (non-embryo) induced pluripotent stem cells (iPSCs). Our novel protocol will allow us to make endothelial cells at scale. We will make our endothelial cells available for drug discovery, organ or tissue printing, high throughput or high content screening, toxicity and efficacy testing, and human disease modeling.

We are developing human platelets (Megakaryocytes) from human (non-embryo) induced pluripotent stem cells (iPSCs) in a two-step process (iPSCs to HSCs and HSCs to Megakaryocytes). Our novel protocols will use small molecules to make platelets, which will allow production of platelets at scale. We will use our platelets as the foundation for a cell therapy for the treatment of blood loss and various blood diseases and disorders, which we are developing.

We are developing human red blood cells (Erythrocytes) from induced pluripotent stem cells (iPSCs) in a two-step process (iPSCs to HSCs and HSCs to Erythrocytes). Our novel protocols will use small molecules to make red blood cells, which will allow production of red blood cells at scale. We will use our red blood cells as the foundation for a cell therapy for the treatment of blood loss and various blood diseases and disorders, which we are developing.

We are developing human long-term hematopoietic stem cells (LT-HSCs) from human (non-embryo) induced pluripotent stem cells (iPSCs). HSCs are rare subsets of hematopoietic cells that are responsible for the life-long production of all blood cell lineages, and for the reconstitution of bone marrow (BM) after transplantation into myeloablative recipients. We will use our LT-HSCs cells as the foundation for cell therapy for bone marrow failure, which we are developing, in particular, as a cell replacement therapy — in lieu of a bone marrow transplant — for patients whose bone marrow stems cells have been permanently damaged or destroyed.